Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
Update: 2025-04-05
Description
Guest: Jennie Taylor, MD
The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
